[go: up one dir, main page]

WO2003045990A3 - Protein-protein interactions involving transforming growth factor beta signalling - Google Patents

Protein-protein interactions involving transforming growth factor beta signalling Download PDF

Info

Publication number
WO2003045990A3
WO2003045990A3 PCT/EP2002/013866 EP0213866W WO03045990A3 WO 2003045990 A3 WO2003045990 A3 WO 2003045990A3 EP 0213866 W EP0213866 W EP 0213866W WO 03045990 A3 WO03045990 A3 WO 03045990A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
growth factor
transforming growth
protein interactions
factor beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/013866
Other languages
French (fr)
Other versions
WO2003045990A2 (en
Inventor
Pierre Legrain
Jean-Michel Gauthier
Frederic Colland
Xavier Jacq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aton SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Priority to AU2002365517A priority Critical patent/AU2002365517A1/en
Publication of WO2003045990A2 publication Critical patent/WO2003045990A2/en
Publication of WO2003045990A3 publication Critical patent/WO2003045990A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to protein-protein interactions involved in transforming growth factor β disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
PCT/EP2002/013866 2001-11-26 2002-11-26 Protein-protein interactions involving transforming growth factor beta signalling Ceased WO2003045990A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365517A AU2002365517A1 (en) 2001-11-26 2002-11-26 Protein-protein interactions involving transforming growth factor beta signalling

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33334801P 2001-11-26 2001-11-26
US60/333,348 2001-11-26
US38453702P 2002-05-31 2002-05-31
US60/384,537 2002-05-31
US42247102P 2002-10-30 2002-10-30
US60/422,471 2002-10-30

Publications (2)

Publication Number Publication Date
WO2003045990A2 WO2003045990A2 (en) 2003-06-05
WO2003045990A3 true WO2003045990A3 (en) 2004-04-01

Family

ID=27406912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013866 Ceased WO2003045990A2 (en) 2001-11-26 2002-11-26 Protein-protein interactions involving transforming growth factor beta signalling

Country Status (2)

Country Link
AU (1) AU2002365517A1 (en)
WO (1) WO2003045990A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059702A1 (en) * 2003-06-20 2007-03-15 Erich Wanker Disease related protein network
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053830A1 (en) * 1997-05-28 1998-12-03 President And Fellows Of Harvard College METHODS AND REAGENTS FOR MODULATING TGF-β SUPERFAMILY SIGNALING
WO1998055512A2 (en) * 1997-06-02 1998-12-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Smad-interacting polypeptides and their use
WO2001064834A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053830A1 (en) * 1997-05-28 1998-12-03 President And Fellows Of Harvard College METHODS AND REAGENTS FOR MODULATING TGF-β SUPERFAMILY SIGNALING
WO1998055512A2 (en) * 1997-06-02 1998-12-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Smad-interacting polypeptides and their use
WO2001064834A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIAO KAI ET AL: "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, as a novel nuclear interaction partner of Smad1.", MOLECULAR AND CELLULAR BIOLOGY, vol. 22, no. 21, November 2002 (2002-11-01), November, 2002, pages 7633 - 7644, XP002251797, ISSN: 0270-7306 *
LABBE E ET AL: "SMAD2 AND SMAD3 POSITIVELY AND NEGATIVELY REGULATE TGFBETA- DEPENDENT TRANSCRIPTION THROUGH THE FORKHEAD DNA-BINDING PROTEIN FAST2", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 2, no. 1, July 1998 (1998-07-01), pages 109 - 120, XP000857311, ISSN: 1097-2765 *
MASSAGUE J ET AL: "TGF-BETA SIGNALLING THROUGH THE SMAD PATHWAY", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, May 1997 (1997-05-01), pages 187 - 192, XP002911610, ISSN: 0962-8924 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K

Also Published As

Publication number Publication date
AU2002365517A8 (en) 2003-06-10
AU2002365517A1 (en) 2003-06-10
WO2003045990A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
WO2002086122A3 (en) Protein-protein interactions in adipocytes
WO2003046176A3 (en) Protein-protein interactions in human immunodeficiency virus
AU2002305450A1 (en) Proteomimetic compounds and methods
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
MXPA05012316A (en) Novel peptides that bind to the erythropoietin receptor.
WO2005095457A3 (en) Immunoglobulins
SG135917A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
UA89017C2 (en) HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
DE60034957D1 (en) Compositions and Methods for Modulating Apoptosis in Cells Expressing BC1-2 Family Proteins
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2007098198A3 (en) Modulation of bone formation
WO2003008454A3 (en) Glycoprotein vi fusion proteins
GEP20094629B (en) Nogo receptor binding protein
WO2002065134A3 (en) Modulators of p53-p300 interactions and screening methods therefor
HUP0402496A2 (en) Growth hormone fusion protein
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2002053726A3 (en) Protein-protein interactions in adipocyte cells
WO2002090544A3 (en) Protein-protein interactions in adipocyte cells (3)
WO2003045990A3 (en) Protein-protein interactions involving transforming growth factor beta signalling
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2003026700A3 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
UA72875C2 (en) Novel proteins which bind human <sub>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-amyloid peptide, polynucleotides which encode theM
WO2002066501A3 (en) PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP